CGM Subsidy News: What Changed for Australians in 2026

If you live with diabetes and use insulin, you’ve probably been watching closely for news about who gets help paying for a continuous glucose monitor (CGM) — a small sensor, usually worn on the arm, that checks your glucose (blood sugar) levels throughout the day and night without finger pricks. In late October 2026, the Medical Services Advisory Committee (MSAC), the independent body that advises the Australian Government on what should be subsidised, made some important decisions — and left one big question unanswered.

The short version

• MSAC has recommended subsidised CGM access be extended to adults with type 3c diabetes (diabetes caused by damage to the pancreas, such as from pancreatitis or pancreatic surgery) and some similar conditions.
• A decision on subsidised CGM for people with insulin-treated type 2 diabetes has been deferred until 2027, disappointing advocates after nearly 8,000 public submissions.
• From 1 October 2026, eligible Omnipod 5 users on the National Diabetes Services Scheme (NDSS) can also use the FreeStyle Libre 3 Plus sensor.
• Existing Dexcom G6 users on the NDSS have been moved across to Dexcom G7 without needing new paperwork.

What’s actually new this round

MSAC reviewed evidence on widening subsidised CGM access beyond type 1 diabetes. According to Diabetes Australia, the committee supported extending subsidy eligibility to adults over 21 with type 3c diabetes and comparable conditions where people are fully dependent on insulin, similar to type 1 diabetes. This recommendation now needs to be formally adopted as government policy before it becomes real funding on the ground — it isn’t automatic.

At the same time, MSAC pushed back its decision on insulin-dependent type 2 diabetes to 2027, citing gaps in the evidence base and uncertainty about cost-effectiveness. This matters because type 2 diabetes is far more common than type 1, and many people using multiple daily insulin injections currently pay full price for CGM sensors — often several hundred dollars a month.

What the evidence and advocacy groups are saying

Diabetes Australia called the type 3c outcome a welcome step forward but said the deferral for type 2 diabetes was especially disappointing, particularly following a 2024 parliamentary inquiry that specifically recommended expanding subsidised CGM to people with type 2 diabetes who need regular insulin. The organisation has flagged priority groups it believes should be fast-tracked once a decision is made, including:

• People using three or more insulin injections a day
• Aboriginal and Torres Strait Islander people using insulin
• People who are pregnant or planning pregnancy
• People diagnosed with type 2 diabetes before age 25

It’s worth being clear about what’s early-stage versus confirmed. The type 3c recommendation has been made by MSAC but still needs sign-off and implementation by government — there’s no confirmed start date yet. The type 2 diabetes decision is genuinely still pending; nothing has been approved or ruled out for 2027.

Who this affects right now

• Type 1 diabetes: No change to existing NDSS eligibility rules — CGM subsidy access continues much as before.
• Type 3c diabetes: Eligibility may be expanded in future, but check with your diabetes team before assuming anything has changed yet.
• Type 2 diabetes (insulin-treated): No new subsidy as of November 2026. People in this group can still apply to the NDSS for special consideration in some circumstances, but broad automatic access is not yet in place.
• Gestational diabetes and prediabetes: These groups are not currently part of the NDSS CGM subsidy scheme.

Device and access updates in Australia

A few practical changes have also rolled out:

• From 1 October 2026, eligible NDSS registrants using an Omnipod 5 insulin pump can pair it with a FreeStyle Libre 3 Plus sensor, giving more device choice.
• NDSS-subsidised Dexcom G6 users have been transitioned to Dexcom G7, reportedly without needing to complete new access forms.

If you’re unsure how these changes affect your own NDSS registration or device choice, the NDSS Helpline (1800 637 700) or your credentialled diabetes educator can talk you through it.

What we still don’t know

There’s no confirmed timeline for when, or if, the type 3c recommendation will become funded policy. Likewise, the 2027 type 2 diabetes decision could still go either way, and some industry voices have suggested funding might realistically take longer to materialise. Costings reported alongside these discussions suggest expanding access to around 16,000 Australians with type 2 and other forms of diabetes could cost over $100 million across four years — a figure government will need to weigh against other health priorities.

What this means for you

• If you have type 3c diabetes, keep an eye on official NDSS updates rather than assuming access has started.
• If you have insulin-treated type 2 diabetes and currently self-fund a CGM, nothing changes immediately — but it’s worth asking your GP or endocrinologist whether you could apply for special consideration in the meantime.
• Check whether any recent device changes (Omnipod 5, Dexcom G7) apply to you, and confirm with your health professional before switching anything.
• Keep your contact and concession details up to date with the NDSS, as eligibility criteria depend on these.

Always talk to your GP, endocrinologist, credentialled diabetes educator or accredited practising dietitian before changing how you monitor or manage your glucose levels.

Where to next

CGM access policy is moving, even if slowly — and Diabetes Clarity will keep tracking it so you don’t have to. While you wait for news, explore our practical guides on reading CGM trends, our low-GI meal ideas, and daily menu plans designed with real Australian pantries in mind.